NCT04451200View on ClinicalTrials.gov

Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

November 30, 2023

Study Completion Date

December 31, 2028

Conditions
Acute LeukemiaMielodysplasic SyndromeMyeloproliferative Neoplasm
Interventions
DRUG

Busulfan Injection

injections doses will be personalized by PK at days -7 and -4

All Listed Sponsors
lead

Institut Paoli-Calmettes

OTHER